FDA
-
-
-
-
-
-
-
Kaleido Biosciences Inc. (KLDO) to Appoint Dr. Alison Long as Chief Medical Officer
-
-
-
-
-
-
-
Kaleido Biosciences Announces New Clinical and Preclinical Data Supporting Advancement of KB295 to a Phase 2 Clinical Study in Mild-to-Moderate Ulcerative Colitis
-
-
-
-
-
-
-
Kaleido Biosciences (KLDO) Reports Positive Results from Non-IND Study Demonstrating Reduction in COVID-19 Related Healthcare Utilization and Recovery Time in Patients with Mild-to-Moderate COVID-19 a
-
-
-
-
-
-
-
Kaleido Biosciences Inc. (KLDO) to Advance KB174 for Hepatic Encephalopathy Based on Positive Top-Line Results from a Clinical Study in Patients with Cirrhosis
-
-
-
-
-
-
-
Kaleido Biosciences Announces Presentation of Clinical Study and Ex Vivo Data Supporting the Development of Novel Microbiome Metabolic Therapies for Hyperammonemia at The International Liver Congress�
-
-
-
-
-
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

